Ensysce Biosciences (ENSC)
NASDAQ:ENSC
Top Page
Ensysce Biosciences
(NASDAQ:ENSC)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.68
▼(-32.28% Downside)
Action:ReiteratedDate:02/04/26
The score is primarily held down by weak financial performance (shrinking TTM revenue, very negative margins, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events provide some offset via added financing and governance/capital-structure actions, but valuation remains hard to justify given ongoing losses and no dividend support.
Positive Factors
Prodrug-based abuse-deterrent platform
Ensysce's prodrug-focused R&D targets abuse-deterrent and overdose-protective opioid/CNS medicines, a structural market need amid opioid regulation. Proprietary formulation science can create durable differentiation versus generics, support regulatory exclusivity, and enable premium positioning for prescribers and payers.
Negative Factors
Heavy cash burn
Sustained negative operating and free cash flow (~-$7.1M TTM) signals dependence on external capital to fund operations and trials. Persistent cash burn heightens refinancing risk, may force dilutive financings, and limits the company's ability to sustain multi-year clinical programs without partner or investor support.
Read all positive and negative factors
Positive Factors
Negative Factors
Prodrug-based abuse-deterrent platform
Ensysce's prodrug-focused R&D targets abuse-deterrent and overdose-protective opioid/CNS medicines, a structural market need amid opioid regulation. Proprietary formulation science can create durable differentiation versus generics, support regulatory exclusivity, and enable premium positioning for prescribers and payers.
Read all positive factors
Ensysce Biosciences (ENSC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.92M
Dividend YieldN/A
Average Volume (3M)89.63K
Price to Earnings (P/E)―
Beta (1Y)1.83
Revenue Growth1.51%
EPS Growth77.64%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,632,307
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)3.83
Price to Sales (P/S)2.73
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.01
Enterprise Value/Gross Profit0.01
Enterprise Value/Ebitda0.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$2.50M
Ensysce Biosciences Business Overview & Revenue Model
Company Description
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin A...
How the Company Makes Money
Ensysce Biosciences makes money primarily through the development and commercialization of its proprietary drug formulations and technologies. The company's revenue model includes licensing agreements and partnerships with pharmaceutical companies...
Ensysce Biosciences Earnings Call Summary
Earnings Call Date:Mar 15, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical achievements, including FDA breakthrough designations and successful trial completions, against a backdrop of financial challenges and reduced funding. The company is making progress toward its goals but needs additional funding to maintain momentum.Positive Updates
Significant Clinical Progress
2023 marked a year of exceptional clinical progress for Ensysce's next-generation analgesics, moving programs closer to commercialization.
Negative Updates
Limited Cash Reserves
The company ended 2023 with $1.1 million in cash and cash equivalents, highlighting the need for additional funding to initiate Phase III trials.
Read all updates
Q4-2023 Updates
Positive
Negative
Significant Clinical Progress
2023 marked a year of exceptional clinical progress for Ensysce's next-generation analgesics, moving programs closer to commercialization.
Read all positive updates
Company Guidance
During Ensysce Biosciences' Q4 2023 earnings call, the company provided detailed guidance on its advancements and future plans. Ensysce reported significant clinical progress with its next-generation opioid analgesics, focusing on the PF614 and PF614-MPAR products. The company completed five clinical trials for PF614, including a human abuse potential study and an analgesic efficacy study. Ensysce plans to initiate Phase III trials for PF614 in the second half of 2024, following FDA feedback. They also received breakthrough therapy designation for PF614-MPAR, highlighting its potential to prevent opioid overdose. Financially, Ensysce ended 2023 with $1.1 million in cash, supplemented by early 2024 warrant exercises and plans to raise additional funds before starting Phase III trials. The company’s R&D expenses decreased in 2023, totaling $7.6 million, with a focus on optimizing manufacturing and preparing for pivotal clinical trials.Ensysce Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.49M | 5.21M | 2.23M | 2.52M | 3.53M | 3.93M |
| Gross Profit | -4.19M | -2.01M | -5.36M | -17.31M | 3.53M | 3.93M |
| EBITDA | -1.92M | -6.73M | -10.72M | -24.22M | -25.93M | 834.82K |
| Net Income | -10.97M | -7.99M | -10.61M | -24.17M | -29.08M | 56.77K |
Balance Sheet | ||||||
| Total Assets | 3.18M | 5.60M | 2.71M | 5.89M | 16.42M | 351.81K |
| Cash, Cash Equivalents and Short-Term Investments | 1.67M | 3.50M | 1.12M | 3.15M | 12.26M | 194.21K |
| Total Debt | 364.07K | 301.66K | 854.70K | 4.43M | 17.21M | 4.27M |
| Total Liabilities | 2.30M | 2.22M | 3.36M | 9.91M | 24.58M | 7.01M |
| Stockholders Equity | 1.20M | 3.71M | -322.86K | -3.71M | -7.88M | -6.44M |
Cash Flow | ||||||
| Free Cash Flow | -7.17M | -7.50T | -10.78M | -17.89M | -8.24M | -1.25M |
| Operating Cash Flow | -7.04M | -7.50T | -10.78M | -17.89M | -8.24M | -1.25M |
| Investing Cash Flow | -123.64K | 0.00 | 0.00 | 4.50K | 0.00 | 183.40M |
| Financing Cash Flow | 4.69M | 9.88T | 8.76M | 8.77M | 20.31M | 1.10M |
Ensysce Biosciences Technical Analysis
Negative
1.01
Price Trends
0.58
Negative
1.05
Negative
1.62
Negative
Market Momentum
>-0.01
Negative
50.64
Neutral
61.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENSC, the sentiment is Negative. The current price of 1.01 is above the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.58, and below the 200-day MA of 1.62, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.64 is Neutral, neither overbought nor oversold. The STOCH value of 61.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENSC.
Ensysce Biosciences Risk Analysis
Ensysce Biosciences disclosed 48 risk factors in its most recent earnings report. Ensysce Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ensysce Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $2.77M | -1.00 | -46.34% | ― | ― | 70.71% | |
43 Neutral | $1.92M | -0.46 | -386.72% | ― | 1.51% | 77.64% | |
41 Neutral | $39.94M | -7.41 | 821.56% | ― | -74.73% | 95.81% | |
| ― | $5.91M | -1.90 | -24.80% | ― | 1371.65% | 64.13% |
* Healthcare Sector Average
ENSC
Ensysce Biosciences
0.53
-2.72
-83.78%
NBY
NovaBay Pharma
1.50
-0.51
-25.34%
GLMD
Galmed Pharmaceuticals
0.50
-1.09
-68.30%
CYCN
Cyclerion Therapeutics
1.51
-1.07
-41.44%
SILO
Silo Pharma
0.34
-0.91
-72.80%
ALZN
Alzamend Neuro
1.05
-8.49
-88.99%
Ensysce Biosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Ensysce Biosciences Shareholders Approve Key Corporate Actions
Positive
Jan 8, 2026
At its annual meeting of stockholders held on January 7, 2026, Ensysce Biosciences, Inc. secured shareholder approval for several key corporate actions that collectively strengthen its capital structure, governance continuity and financial oversig...
Private Placements and Financing
Ensysce Biosciences Secures $4M Financing for PF614
Positive
Nov 17, 2025
On November 14, 2025, Ensysce Biosciences closed a $4 million convertible preferred stock financing, with the potential for an additional $16 million over the next 24 months. This funding will accelerate the Phase 3 clinical program for PF614, a f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.